Advanced in Epilepsy

Hitoshi Osaka

Shimotsuke, JP 
Advanced in Epilepsy
Shimotsuke, JP 
OverviewLocationsClinical Research

Overview

Hitoshi Osaka practices in Shimotsuke, Japan. Mr. Osaka is rated as an Advanced expert by MediFind in the treatment of Epilepsy. His top areas of expertise are Pelizaeus-Merzbacher Disease, CACH Syndrome, Leigh Syndrome, and West Syndrome.

His clinical research consists of co-authoring 200 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 30 articles in the study of Epilepsy.

Gender
Male

Locations

Shimotsuke, Japan
Other Locations
Tochigi, 3290498, Japan
Japan
Osaka, Japan
Yokohama, Japan
Kurashiki, 7010193, Japan
Ministry of Agriculture, Forestry and Fisheries
Tokoname, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 3, Multicenter, Open-label Extension Study of Buccally Administered MHOS/SHP615 in Pediatric Patients With Status Epilepticus (Convulsive) in Community Settings
A Phase 3, Multicenter, Open-label Extension Study of Buccally Administered MHOS/SHP615 in Pediatric Patients With Status Epilepticus (Convulsive) in Community Settings
Enrollment Status: Completed
Publish Date: September 14, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Phase 3, Multicenter, Open-label Study to Determine the Efficacy, Safety, and Pharmacokinetics of Buccally Administered MHOS/SHP615 in Pediatric Patients With Status Epilepticus (Convulsive) in the Hospital or Emergency Room
A Phase 3, Multicenter, Open-label Study to Determine the Efficacy, Safety, and Pharmacokinetics of Buccally Administered MHOS/SHP615 in Pediatric Patients With Status Epilepticus (Convulsive) in the Hospital or Emergency Room
Enrollment Status: Completed
Publish Date: July 31, 2020
Intervention Type: Drug
Study Phase: Phase 3
View 1 Less Clinical Trial

200 Total Publications

Compound heterozygous variants of CACNA1H change channel properties and contribute to intractable epilepsy with myoclonic-atonic seizures.
Compound heterozygous variants of CACNA1H change channel properties and contribute to intractable epilepsy with myoclonic-atonic seizures.
Journal: Journal of human genetics
Published: September 06, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Osaka's expertise for a condition
ConditionClose
View All 27 Advanced Conditions
View All 75 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile